ARAV Trade on Nov 20, 2019 09:42 from beno: Tradervue User Stock Trades.

Gravatar

Shared by
beno

 

Fundamentals

Picture: $500m registered in September 2017 S-3, 20.25m ATM prospectus in March 2019 (unused)
Healthy fundamentals but will need more cash for Phase 2-4 of AVB-500
Many cancer treament BioTechs running like crazy

Shares Outstanding: 11.3m
Cash: 44.9m
Current liabilities: 6.385m
Current ratio: 7.59
NWC (total current assets - total current liabilities): 42.083m
Monthly Burn rate (net cash used in operating activities / months): 1.335m
Estimated current cash: 42.23m
Accumulated deficit: 465.78m
Book value per share (Stock holder equity / Shares outstanding): 4.20

Technical Analysis

-Huge PM run going above all levels since late 2017
-Faded after high of 29
-Important levels: 9.50, 13, 15, 20, 25 and 29

Catalysts / News

Positive data for AVB-500 Phase 1b trial for Ovarian Cancer

Original Plan / Strategy

Was shortable due to higher float, wanted to use First Test on 20, 15 and 13 level, only the 13 level set up nicely for me.

Review

Had my scaled orders in but only my first got filled, stock gave me an opportunity to take profits before my other orders got filled so I took the profits and canceled other orders. I would have gotten stopped out if I didn't take the immediate opportunity.


Execution detail:

Date/time Symbol Side Price Position
2019-11-20 09:42:51 ARAV sell $12.970 short
2019-11-20 09:44:04 ARAV buy $12.640 0


Leave a comment about this trade!

You need to log into your Tradervue account to leave a comment. If you don't have one,
it takes just a few seconds to sign up, and it's free!

View plans, Sign up for free, or Log in